Immatics at AACR Meeting 2019 (July 19-22) in San Francisco, California

| News, USA

Immatics Will Present Initial Data on Its ACTolog® Multi-target T-cell Therapy Clinical Trial

Meet Immatics at the Meeting of the American Association for Cancer Research (AACR) – “Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy” at Hyatt Regency in San Francisco, California. 

Saturday, July 20, 8-10am PST

Plenary Session 1: Cellular Therapy Clinical Updates I

Cellular immunomonitoring for the first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog® IMA101-101)

Speaker: Anna Nowak, Scientist Immunology, Immatics

 

Saturday, July 20, 12:30-2:30pm PST

Poster Session A

A14 Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers

Principal Investigator: Apostolia M. Tsimberidou, MD Anderson Cancer Center

Presenter: Harpreet Singh, CEO Immatics

 

Sunday, July 21, 8-10am PST

Plenary Session 5: Cellular Therapy Clinical Updates II

Phase I adoptive cellular therapy trial with endogenous CD8+ T cells (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers

Principal Investigator: Apostolia M. Tsimberidou, MD Anderson Cancer Center

Speaker: Harpreet Singh, CEO Immatics

 

Sunday, July 21, 10:30am-12:15pm PST

Plenary Session 6: Optimization of Target Antigens for TCR and TIL

Novel naturally presented targets for personalized T-cell therapies

Speaker: Harpreet Singh, CEO Immatics 

 

Sunday, July 21, 4:30pm-6:30pm PST

Poster Session B

B15 “Cellular immunomonitoring for the first personalized adoptive cellular therapy trial using defined multiple targets (ACTolog® IMA101-101)” 

Presenter: Anna Nowak, Scientist Immunology, Immatics

 

We’re looking forward to interesting and exciting discussions.

Further information on the AACR special conference on Immune Cell Therapies for Cancer here.

Press Contact

Anja Heuer

Corporate Communications,
Immatics Biotechnologies GmbH

+49 89 540 415 606

Go back

We use cookies to ensure that we give you the best experience on our website.